New drug cocktail shows promise for liver cancer in hepatitis b patients
NCT ID NCT04180072
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of two drugs, atezolizumab and bevacizumab, in 51 people with advanced liver cancer who also have chronic hepatitis B. The goal is to see if the treatment can shrink tumors and control the disease. Participants receive the drugs every three weeks, and researchers monitor tumor response and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atezolizumab (Tecentriq) and bevacizumab (Avastin)
What this could lead to
If successful, this could offer a new treatment option for advanced liver cancer in people with chronic hepatitis B, potentially shrinking tumors and extending life.
What could go wrong
This is a small, single-arm trial with no comparison group, so results may not be definitive. The drugs can cause serious side effects like liver damage or bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chang Gung Memorial Hospital
Linkou District, Taiwan
-
China Medical University Hospital
Taichung, Taiwan
-
Mackay Memorial Hospital
Taipei, Taiwan
-
National Cheng Kung University Hospital
Tainan, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan
-
Taichung Veterans General Hospital
Taichung, Taiwan
-
Taipei Veterans General Hospital
Taipei, Taiwan